Alumis Raises $250 Million in Downsized IPO, Private Placement

Alumis Inc., a clinical stage biopharmaceutical company, raised $250 million in a downsized initial public offering with a concurrent private placement, pricing its shares at the bottom of a marketed range.

The company sold about 13.1 million shares Thursday for $16 each after marketing 17.65 million for $16 to $18, according to a statement.